share_log

Legend Biotech Says Phase 3 Trial of Multiple Myeloma Drug Candidate Meets Primary Endpoint; Shares Rise

Legend Biotech Says Phase 3 Trial of Multiple Myeloma Drug Candidate Meets Primary Endpoint; Shares Rise

傳奇生物科技稱多發性骨髓瘤候選藥物的 3 期試驗達到主要終點; 股價上升
MT Newswires ·  2023/01/27 09:25

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論